Data as of Sep 17
| -0.10 / -1.72%|
The 2 analysts offering 12-month price forecasts for Galectin Therapeutics Inc have a median target of 24.00, with a high estimate of 32.00 and a low estimate of 16.00. The median estimate represents a +318.85% increase from the last price of 5.73.
The current consensus among 2 polled investment analysts is to Buy stock in Galectin Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.